Remdesivir and standard care vs placebo or usual care
Serious adverse events at up to day 28 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
- RR 0.84 [0.65, 1.07]4 studies · 2498 participantsLow